DEPRESSIVE EPISODE OF BIPOLAR DISORDER WITH HOMOEOPATHY

AN OPEN-LABEL CLINICAL STUDY IN DEPRESSIVE EPISODE OF BIPOLAR DISORDER WITH ADJUNCTIVE HOMOEOPATHIC TREATMENT - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089537

Enrollment

Registered

2025-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F313- Bipolar disorder, current episodedepressed, mild or moderate severity

Interventions

Intervention1: Individualised Homoeopathic Medicines: After enrollment the case will be repertorised. Appropriate potentized Individualised Homoeopathic Medicine will be administered in minimum dos

Eligibility

Inclusion criteria

Inclusion criteria: Individuals aged 19 to 65 years of both sexes who meet the ICD11 criteria for a depressive episode in bipolar disorder Diagnosed cases of bipolar disorder with or without psychotic symptoms Patients scoring above 18 on the Bipolar Depression Rating Scale Individuals willing to initiate continue or adhere to conventional medication while receiving adjunctive individualized Homoeopathic treatment

Exclusion criteria

Exclusion criteria: Individuals with depression symptoms other than BPAD including schizophrenia schizoaffective disorder and substance use disorder medication induced BPAD Patients currently experiencing a manic or hypomanic episode Pregnant and lactating women Individuals diagnosed with personality disorders such as borderline or avoidant personality disorder Known case of Rapid mania cycle

Design outcomes

Primary

Measure	Time frame
The effectiveness of adjunctive individualized homoeopathic treatment in the depressive episode of BPAD will be assessed using the Bipolar Depression Rating Scale base line and monthly assessment till completion of studyTimepoint: Base line and monthly assessment till completion of study	—

Secondary

Measure	Time frame
The improvement in quality of life (QoL) in individuals with a depressive episode of BPAD, will be assessed using the Quality of Life in Bipolar Disorder (QoL-BD) scale.Timepoint: Changes in scores from baseline to the end of treatment will be analysed to evaluate improvements in depressive symptoms of Bipolar Affective Disorder (BPAD). Additionally, the number of depressive episodes over one year will be recorded and compared with quality-of-life scores to assess the impact of symptom severity on overall well-being.;The side effects of antidepressant treatment will be assessed using the Udvalg for Kliniske Unders gelser (UKU) Side Effect Rating Scale during follow-upTimepoint: Baseline at 3rd,6th,9th month and at the conclusion of the study (12th month)	—

Measure

Time frame

The improvement in quality of life (QoL) in individuals with a depressive episode of BPAD, will be assessed using the Quality of Life in Bipolar Disorder (QoL-BD) scale.Timepoint: Changes in scores from baseline to the end of treatment will be analysed to evaluate improvements in depressive symptoms of Bipolar Affective Disorder (BPAD). Additionally, the number of depressive episodes over one year will be recorded and compared with quality-of-life scores to assess the impact of symptom severity on overall well-being.;The side effects of antidepressant treatment will be assessed using the Udvalg for Kliniske Unders gelser (UKU) Side Effect Rating Scale during follow-upTimepoint: Baseline at 3rd,6th,9th month and at the conclusion of the study (12th month)

—

Countries

India

Contacts

Public ContactDr S KARUNAKARA MOORTHI

National Homoeopathy Research Institute in Mental Health

drjaiguru@gmail.com8281502571

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026